- Home
- MTEM vs SBFM Comparison
MTEM vs SBFM Comparison
Compare MTEM & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTEM
- SBFM
- Stock Information
- Founded
- MTEM 2001
- SBFM 2006
- Country
- MTEM United States
- SBFM United States
- Employees
- MTEM N/A
- SBFM N/A
- Industry
- MTEM Biotechnology: Biological Products (No Diagnostic Substances)
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- MTEM Health Care
- SBFM Health Care
- Exchange
- MTEM Nasdaq
- SBFM Nasdaq
- Market Cap
- MTEM 9.7M
- SBFM 3.7M
- IPO Year
- MTEM N/A
- SBFM N/A
- Fundamental
- Price
- MTEM $0.71
- SBFM $3.14
- Analyst Decision
- MTEM
- SBFM
- Analyst Count
- MTEM 0
- SBFM 0
- Target Price
- MTEM N/A
- SBFM N/A
- AVG Volume (30 Days)
- MTEM 13.4M
- SBFM 90.8K
- Earning Date
- MTEM 11-11-2024
- SBFM 11-11-2024
- Dividend Yield
- MTEM N/A
- SBFM N/A
- EPS Growth
- MTEM N/A
- SBFM N/A
- EPS
- MTEM N/A
- SBFM N/A
- Revenue
- MTEM $25,470,000.00
- SBFM $30,481,982.00
- Revenue This Year
- MTEM N/A
- SBFM $86.70
- Revenue Next Year
- MTEM N/A
- SBFM $126.76
- P/E Ratio
- MTEM N/A
- SBFM N/A
- Revenue Growth
- MTEM N/A
- SBFM 109.82
- 52 Week Low
- MTEM $0.30
- SBFM $2.42
- 52 Week High
- MTEM $6.48
- SBFM $660.00
- Technical
- Relative Strength Index (RSI)
- MTEM 38.68
- SBFM 52.62
- Support Level
- MTEM $0.31
- SBFM $2.85
- Resistance Level
- MTEM $1.34
- SBFM $3.05
- Average True Range (ATR)
- MTEM 0.14
- SBFM 0.14
- MACD
- MTEM -0.05
- SBFM 0.03
- Stochastic Oscillator
- MTEM 34.48
- SBFM 85.29
About MTEM Molecular Templates Inc.
Molecular Templates Inc is a clinical-stage biopharmaceutical company focused on developing therapeutic agents that selectively target tumor cells for the treatment of individuals living with cancer. Its pipeline products are MT-6402, MT-8421 and MT-0169.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.